Dynavax Technologies Corporation (NASDAQ: DVAX)
Dynavax is having an incredibly strong start to the day today, and for good reason. The company released a PR informing investors of details with regard to a Phase 3 clinical trial. Today, we’ll talk about the trial, what we’re seeing in the market, and what we can expect to see from DVAX ahead.
Trade smarter and make more money with Tradespoon!
DVAX Releases Key Data
As mentioned above, Dynavax Technologies released important data today. The data was a result of a sub-group in a Phase 3 trial of HEPLISAV-B. The sub-group the data surrounded was the HBV-23 group.
In the data released by DVAX, we learned that when the treatment was provided as two doses over the course of a month, significantly higher seroprotection rates were induced than in the approved hepatitis B vaccine Engerix-B when administered as three doses over six months.
In a statement, Rob Janssen, M.D., CMO at DVAX, had the following to offer:
“Hepatitis B remains an important health problem in the United States with approximately 20,000 new infections in adults every year. Although hepatitis B vaccines have been available for 25 years and served an important role in preventing the disease, approved hepatitis B vaccines have several limitations, including lower protection rates in some populations… We were encouraged to see that HEPLISAV-B administered as two doses over one month provided a significantly higher rate of seroprotection in these individuals than the existing hepatitis B vaccine. The lower immunology observed in sub-groups in the Engerix-B arm of this Phase 3 study demonstrates the clinical need for a hepatitis B vaccine that can provide higher rates of seroprotection with fewer doses to adequately protect adults against the consequences of this chronic viral infection.”
How The Stock Reacted To The News
As we know, the news moves the market. In the case of Dynavax Technologies, the news was overwhelmingly positive. So naturally, a positive reaction is being seen. Currently (in pre-market trading), DVAX is trading at $10.75 per share after a gain of 5.91%.
What We Can Expect To See Moving Forward
Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from Dynavax Technologies. At the end of the day, the company is doing incredible things with HEPLISAV-B and, as positive data continues to be released surrounding the vaccine, we’re likely to see more and more gains. At the end of the day, based on the results released thus far, I’m expecting the vaccine to be approved, leading to a strong line of revenue and a high chance of profits.
Don’t waste your time! Click here to find winning trades in minutes!
Never Miss The News Again!
Do you want real time, actionable stock market news delivered to your inbox as it happens? Join our mailing list below! (Free for a limited time only.)
[Image Courtesy of Flickr]